David DiLillo

David DiLillo

Company: Regeneron

Job title: Associate Director, Immuno-Oncology


David DiLillo is a Senior Staff Scientist in the Immuno-Oncology department at Regeneron Pharmaceuticals in New York, where he leads a team investigating novel T cell-retargeting technologies. His team is responsible for IND-enabling as well as mechanistic in vitro and in vivo studies using Regeneron’s unique bispecific antibody platform to identify immune-targeted therapeutics to treat liquid and solid tumors. His team also actively investigates chimeric antigen receptor (CAR) T cell biology in similar model systems. Dr. DiLillo holds a Ph.D. in Immunology from Duke University, where he studied non-classical B cell effector functions, and he completed his postdoctoral studies in Fc-receptor biology at the Rockefeller University.



Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3Bispecifics and CAR T Cells 4:00 pm

Two competing platforms exist for redirecting T cells to recognize and kill tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T cells We have developed preclinical in vitro and in vivo models to mechanistically compare these two technologies and will discuss our findings as well as the clinical implicationsRead more

day: Day Two

Chair’s Closing Remarks & End of Day One 5:05 pm

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.